Anlon Healthcare Ltd - 544497 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Anlon Healthcare reported strong audited financial results for FY26, with cons. total income up 43% to Rs.172.22 cr and PAT up 42% to Rs.29.09 cr. The company also strengthened its long-term growth platform through strategic acquisitions.
May 30 2026 11:37:06
Anlon Healthcare Ltd - 544497 - Board Meeting Outcome for To Consider And Approve Financial Results For The Quarter And Year Ended March 31, 2026
Anlon Healthcare's board approved its consolidated FY26 results, reporting revenue of ₹171.97 cr and net profit of ₹29.09 cr. The company also approved allocating ₹23.33 cr from IPO proceeds for strategic acquisitions, mergers, and manufacturing upgrades.
May 29 2026 12:23:15
Anlon Healthcare Ltd - 544497 - Board Meeting Intimation for To Consider And Approve The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 Along With The Auditors'' Report Thereon.
Anlon Healthcare's Board of Directors is scheduled to meet on May 29, 2026. The agenda includes considering and approving the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, along with the Auditors' report.
May 23 2026 17:49:41
Anlon Healthcare Ltd - 544497 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Anlon Healthcare's Q4 FY26 Monitoring Agency Report confirmed that IPO funds were utilized for operational activities, including the acquisition of Bizotic Life Science and Apiqo Organics for Rs 9.21 crores, aligned with shareholder-approved plans.
May 13 2026 13:50:10
Read More